TGFB1 and Hyperglycemia: This reduction in TGF‐β1 level (55 ± 1% decrease, percentage over 14 week Control group, p < 0.001; Figure 4F) also coincided with exacerbated hyperglycemia and T1D progression in the Control group from week 14 to week 20 (Figure 2A).